However, near-normalisation of hyperglycaemia using insulin (which is potentially also possible through GLP-1-mediated improvements in glycaemic control) may at least partially restore the insulinotropic action of GIP in people with type 2 diabetes (Fig. 3 [24]), and co-administration of GIP with a GLP-1 receptor agonist leads to greater weight loss in diet-induced obese (DIO) mice relative to treatment with the GLP-1 receptor agonist alone [88]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.